A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients

Michael Duerr,Eva Schrezenmeier,Lukas Lehner,Leon Bergfeld,Petra Glander,Stephan Rodrigo Marticorena Garcia,Christian E. Althoff,Ingolf Sack,Susanne Brakemeier,Kai-Uwe Eckardt,Klemens Budde,Fabian Halleck

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients

2019

Michael Duerr
Eva Schrezenmeier
Lukas Lehner
Leon Bergfeld
Petra Glander
Stephan Rodrigo Marticorena Garcia
Christian E. Althoff
Ingolf Sack
Susanne Brakemeier
Kai-Uwe Eckardt
Klemens Budde
Fabian Halleck

Background Only a few prospective trials exist regarding the use of novel direct-acting antiviral agents (DAAs) in kidney transplant recipients (KTR) with chronic hepatitis C virus (HCV) infection.

Keywords:

Intensive care medicine
Hepatitis C virus
Prospective cohort study
Sofosbuvir
Daclatasvir
Medicine
Internal medicine
Kidney
Diabetes mellitus
Voxilaprevir
Gastroenterology
Clinical trial
Kidney transplantation
Transplantation
Liver biopsy
Nephrology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations